TIP-11. MOMENTUM-1: a multicenter, randomized, open-label, phase 2 study of [177Lu]Lu-DOTA-TATE in adults with progressive grade 1-3 meningioma (RTOG 3523) Article Swipe
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/neuonc/noaf201.1671
· OA: W4416139865
BACKGROUND While most meningiomas are classified as low-grade tumors with indolent behavior, a subset is characterized by a more aggressive clinical course and patients undergo repeated resections and courses of radiation. Once these therapies fail, prognosis is poor and progression-free survival (PFS) rates at 6 months (PFS-6) are estimated to only be 43.6% for WHO grade 1 and 38% for WHO grade 2/3 meningiomas. Effective medical therapies are limited. Somatostatin receptor 2 (SSTR2) is expressed in a majority of meningiomas and represents a suitable treatment target. [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) is an SSTR2-targeted radioligand therapy, established as standard of care in the treatment of certain neuroendocrine tumors. Two ongoing non-randomized studies of 177Lu-Dotatate in meningiomas have reported encouraging efficacy compared to historical benchmarks. METHODS/STUDY DESIGN The MOMENTUM-1 study (RTOG 3523, NCT#06955169) is a multicenter, randomized, open-label study of 177Lu-Dotatate in adult patients with progressive intracranial WHO grade 1-3 meningiomas. Up to 130 eligible subjects are randomized in a 2:1 fashion to 177Lu-Dotatate at 7.4 GBq (200 mCi) every 4 weeks for 4 (+2 optional) doses or standard of care (SOC) medical therapy as defined by the protocol and deemed appropriate by the local investigator. Treatment responses are assessed by gadolinium-enhanced MRI brain and [68Ga]Ga-DOTA-TATE (68Ga-Dotatate) PET imaging. At time of progression, cross-over from the SOC to the interventional treatment arm is allowed. The primary endpoint is PFS. Secondary endpoints include PFS-6, OS-12, OS, response assessments (ORR, DCR), safety/tolerability, and patient-reported outcomes. RESULTS/CONCLUSION MOMENTUM-1 is a multicenter, randomized, open-label, phase II study of 177Lu-Dotatate in adult patients with progressive WHO grade 1-3 meningioma. This clinical trial is expected to start enrolling patients in the United States in the third quarter of 2025. Details on study design, eligibility criteria for subject enrollment and study site eligibility criteria will be presented.
